Cargando…
RANK-C Expression Sensitizes ER-Negative, EGFR-Positive Breast Cancer Cells to EGFR-Tyrosine Kinase Inhibitors (TKIs)
Background: We have previously shown that overexpression of RANK-c in ER-negative breast cancer cell lines attenuates aggressive properties of cancer cells, partially through a RANK-c/EGFR interaction. EGFR inhibition through TKIs in breast cancer has been tested in triple-negative disease settings...
Autores principales: | Sirinian, Chaido, Papanastasiou, Anastasios D., Degn, Soren E., Frantzi, Theodora, Aronis, Christos, Chaniotis, Dimitrios, Makatsoris, Thomas, Koutras, Angelos, Kalofonos, Haralabos P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8619104/ https://www.ncbi.nlm.nih.gov/pubmed/34828291 http://dx.doi.org/10.3390/genes12111686 |
Ejemplares similares
-
Analysis of RANK-c interaction partners identifies TRAF3 as a critical regulator of breast cancer aggressiveness
por: Sirinian, Chaido, et al.
Publicado: (2022) -
Correction to: Identification of novel human RANK isoforms generated through alternative splicing. Implications in breast cancer cell survival and migration
por: Papanastasiou, Anastasios D., et al.
Publicado: (2018) -
Identification of novel human receptor activator of nuclear factor-kB isoforms generated through alternative splicing: implications in breast cancer cell survival and migration
por: Papanastasiou, Anastasios D, et al.
Publicado: (2012) -
Cellular Senescence in Normal Mammary Gland and Breast Cancer. Implications for Cancer Therapy
por: Sirinian, Chaido, et al.
Publicado: (2022) -
PIOS (Patras Immunotherapy Score) Score Is Associated with Best Overall Response, Progression-Free Survival, and Post-Immunotherapy Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) Treated with Anti-Program Cell Death-1 (PD-1) Inhibitors
por: Dimitrakopoulos, Foteinos-Ioannis, et al.
Publicado: (2020)